Orthofix Medical (OFIX) to Release Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX) will likely be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Orthofix Medical to post earnings of $0.06 per share and revenue of $212.72 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Orthofix Medical Price Performance

OFIX stock opened at $17.95 on Monday. The company has a 50 day simple moving average of $17.94 and a 200 day simple moving average of $17.33. The stock has a market cap of $685.87 million, a price-to-earnings ratio of -5.73 and a beta of 1.10. Orthofix Medical has a 1 year low of $12.08 and a 1 year high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.

Insiders Place Their Bets

In other news, CEO Massimo Calafiore sold 9,203 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the sale, the chief executive officer now directly owns 124,151 shares in the company, valued at $2,127,948.14. This represents a 6.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Julie Andrews sold 4,655 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total transaction of $83,277.95. Following the sale, the chief financial officer now owns 28,312 shares of the company’s stock, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,442 shares of company stock valued at $436,883 in the last ninety days. 2.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Friday, January 31st. Roth Mkm reiterated a “buy” rating and set a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and upped their price objective for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. Finally, Canaccord Genuity Group initiated coverage on shares of Orthofix Medical in a report on Wednesday, January 22nd. They set a “buy” rating and a $24.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.33.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.